Core Insights - Maria Ford, President of U.S. Commercial & Industrial Sales at DEWALT, has joined the Forbes Business Development Council to share insights on the construction industry and empower the next generation of tradespeople [1][7] Company Overview - DEWALT is a brand under Stanley Black & Decker, recognized as a leader in total jobsite solutions, providing tools and technologies designed to enhance safety and productivity on construction sites [9] Leadership and Advocacy - Ford has a strong background in the industry, having started her career at Stanley Black & Decker in 1998 and progressively taking on more responsibilities in sales and marketing [5] - She is a vocal advocate for skilled trades, actively inspiring future workers through speeches, op-eds, and media engagements [4] Financial Impact - Ford oversees DEWALT's U.S. Commercial & Industrial Sales division, which generates $2 billion in revenue, focusing on empowering professionals through advanced tools and technology solutions [6]

Financial Data and Key Metrics Changes - Total revenue grew 32% to $18,500,000 compared to $14,000,000 in the same quarter last year [22] - Net income was $4,000,000, a significant improvement from a net loss of $2,900,000 in the prior year [6][27] - Basic earnings per share increased to $0.65 from a loss of $0.52 in the same quarter last year [6][27] - Adjusted EBITDA rose to $3,900,000 from $900,000 in the prior year [6][27] Business Line Data and Key Metrics Changes - ADHD portfolio net revenue increased by 25% to $15,400,000 compared to $12,300,000 in Q3 of the previous year [22] - Pediatric portfolio net revenue surged 77% to $3,100,000 from $1,700,000 in the same quarter last year [22][14] Market Data and Key Metrics Changes - ADHD prescriptions were approximately 94,000 during the third quarter, reflecting a return to normalized market conditions following previous shortages [10] - The pediatric business saw a rebound due to a return to growth plan and improved payer coverage [14][15] Company Strategy and Development Direction - The company has focused on its prescription pharmaceutical business, halting clinical development and selling its consumer health business [7] - Future growth is expected to be driven by leveraging the A2 RxConnect platform and pursuing additional in-licensed or acquired products [8][19] - The company aims to maintain a balanced focus on both ADHD and pediatric portfolios for growth [18] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the operational and financial performance, highlighting the achievement of positive income from operations for the second consecutive quarter [5][6] - The company is optimistic about future growth, particularly in the ADHD and pediatric segments, and is focused on operational efficiencies [18][19] Other Important Information - Gross margin for the third quarter was 69%, down from 74% in the same quarter last year, with expectations for improvement as inventory issues are resolved [22][25] - The company paid down $2,500,000 in long-term debt during the quarter, maintaining compliance with all debt covenants [29] Q&A Session Summary Question: Were there any one-time effects in the ADHD or pediatric business this quarter? - Management confirmed that the growth was organic and driven by optimization efforts, with no one-time effects impacting the numbers [35] Question: What are the expectations for the ADHD franchise moving forward? - Management expects continued growth in the ADHD franchise, supported by optimization efforts and a balanced focus on both ADHD and pediatric products [36][37] Question: What is the potential for the pediatric business? - Management indicated realistic growth expectations but does not foresee returning to a $25,000,000 annual business, aiming for something north of current levels [39][40] Question: What are the main factors affecting business development and asset acquisition? - The main gating factor is finding the right asset that complements the company's capabilities and therapeutic focus, with a preference for commercial-ready products [41][42] Question: What impact do tariffs have on the company? - Management stated that tariffs have a minimal impact as all ADHD products are manufactured in the U.S., with only small components sourced internationally [46][47] Question: Can you elaborate on the return to growth plan for the pediatric business? - The plan involved deploying the sales force against more pediatric targets and expanding coverage through creative contracting with payers [54][56] Question: What is the breakeven revenue number based on current operating expenses? - The breakeven revenue is approximately $15,000,000 on a quarterly basis, with a cash-based breakeven closer to $13,100,000 [61][62]

Core Viewpoint - Recordati S.p.A. has approved its 2025-2027 three-year plan, targeting significant revenue and income growth through organic expansion and strategic acquisitions [1][2][7] Financial Targets - Net Revenue is projected to be between €3,000 million and €3,200 million, driven by strong organic growth in both Specialty & Primary Care and Rare Diseases segments [3][5] - EBITDA is expected to range from €1,140 million to €1,225 million, maintaining a margin of at least 38% [5] - Adjusted Net Income is forecasted to be between €770 million and €820 million [5] Growth Drivers - The Specialty & Primary Care business is anticipated to grow at a mid-single digit CAGR of approximately 3.5-4.5% from 2024 to 2027, while the Rare Diseases segment is expected to achieve a double-digit CAGR of 17-20% during the same period [3] - The company plans to leverage recent FDA approvals, such as the expanded label for Isturisa, increasing its peak sales target for the product to between €550 million and €650 million [4] Business Development Strategy - Recordati will continue to focus on organic growth, complemented by business development and M&A activities, while investing in lower-risk pipeline opportunities [1][7] - The company aims to maintain a net debt level between 1.7-2.0 times EBITDA, with flexibility for temporary increases for high-quality acquisitions [6] Recent Performance - In Q1 2025, Recordati reported revenue of €680 million, reflecting an 11.9% increase compared to Q1 2024, with notable growth in both business units [8] - Specialty and Primary Care revenue was €408.6 million, up 3.3%, while Rare Diseases revenue reached €254.8 million, a 29.0% increase [8]

Financial Data and Key Metrics Changes - In Q4 2024, net product revenues reached a record $181.9 million, up 22% year-over-year [42] - For the full year 2024, net product revenues were a record $631.4 million, up 11% year-over-year [42] - Adjusted EBITDA grew by 9% year-over-year, reaching a record $401.2 million for 2024 [47] - GAAP net income for Q4 was $12.5 million, down from $31.9 million in Q4 2023, while full year net income was $69.2 million, up from $48.2 million in 2023 [46] Business Line Data and Key Metrics Changes - Jornay PM generated net revenue of $29.3 million in Q4 2024, with full year pro forma net revenue of $100.7 million, expected to exceed $135 million in 2025, representing over 34% growth [12][42] - Belbuca achieved net revenue of $55.2 million in Q4 2024, up 12% year-over-year, and $211.3 million for the full year, up 16% year-over-year [43] - Xtampza ER net revenue was $51.5 million in Q4, up 6% year-over-year, and $191.3 million for the full year, up 8% year-over-year [44] - Nucynta franchise net revenue was $41.8 million in Q4, down 11% year-over-year, and $176.5 million for the full year, down 7% year-over-year [45] Market Data and Key Metrics Changes - The ADHD market has been growing at an average rate of 6% from 2019 to 2024, with stimulant medications comprising almost 90% of the market [21] - Jornay PM prescriptions grew 29% year-over-year in Q4 2024, with a total of 636,200 prescriptions for the full year, up 31% compared to 2023 [12][27] Company Strategy and Development Direction - The company aims to drive significant growth in Jornay, maximize the pain portfolio, and strategically deploy capital to create shareholder value [16][19] - The focus is on expanding and diversifying the portfolio through business development, particularly in ADHD and neuropsychiatry [62] - The company plans to invest in raising awareness of Jornay among healthcare professionals and patients, with targeted investments expected to impact growth primarily in 2026 and beyond [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong financial position, with net leverage expected to be less than one time by the end of 2025 [53] - The company anticipates a modest decline in revenue in Q1 2025 due to typical dynamics, but expects over 10% adjusted EBITDA growth for the year [50][51] - Management highlighted the importance of disciplined capital deployment and the potential for significant growth in the ADHD market [62] Other Important Information - The company repurchased $60 million in shares during 2024, with $90 million remaining in the share repurchase program authorized through Q2 2025 [52] - The acquisition of Ironshore Therapeutics and its lead medicine Jornay PM is seen as a strategic move to enter the neuropsychiatry market [9][66] Q&A Session Summary Question: Path for Collegium over the next three to five years and update on business development opportunities - Management indicated a focus on both organic and inorganic growth, particularly in ADHD and neuropsychiatry, while maintaining a strong financial position [58][62] Question: Synergies realized from the integration of Ironshore - Management noted typical synergies related to senior management overlap and G&A but emphasized the strategic investment in Jornay as the primary focus [66] Question: Impact of the NO PAIN Act on the pain treatment category - Management stated that the NO PAIN Act had no impact on their portfolio as it primarily focuses on inpatient settings, while their products are retail-based chronic pain therapies [67] Question: Sales force expansion and coverage of ADHD prescribers - The expanded sales force will cover 60% of the long-acting ADHD market, targeting approximately 23,000 healthcare professionals [79] Question: Long-term planning for generic entry of Belbuca and Nucynta - Management expressed confidence that no party currently has the necessary combination of ingredients and regulatory clearance to launch competitive generics against their pain products [81]

Core Insights - Intapp has launched the DealCloud Activator, an AI-powered growth platform aimed at enhancing business development practices for professionals in advisory, legal, and capital markets firms [1][2]. Product Features - DealCloud Activator utilizes AI and behavioral science to align business development efforts with strategic goals, integrate new partners, and drive firmwide growth [2]. - The platform provides real-time insights and actionable nudges to support client relationships throughout the client lifecycle without disrupting daily routines [3]. - Key features include relationship and opportunity signals, behavioral nudges, tech stack integration, holistic data pictures, network management and visualization, personalized updates, Activator coaching, and performance metrics [6]. Market Position - Intapp's software is designed to help professionals unlock knowledge, relationships, and operational insights, thereby increasing value for their firms [5]. - The company serves top firms across various sectors, including accounting, consulting, investment banking, legal, private capital, and real assets, leveraging applied AI for competitive advantage [5].